Grail Shares Rise After TD Cowen Lifts Rating Despite Trial Setback
Grail Inc. stock climbed 6.2% Wednesday following TD Cowen's upgrade to Buy from Hold and a revised $65 price target. The upgrade comes after the company's pivotal NHS Galleri trial failed to meet its primary endpoint, a result that previously pushed shares down roughly 60%. TD Cowen highlights a $70 billion total addressable market for multi-cance…